Barrett’s Esophagus and Cancer Risk: How Research Advances Can Impact Clinical Practice

키워드

참고문헌 (133)

1. Paull A, "The histologic spectrum of Barrett’s esophagus", N Engl J Med, 295, pp.476~480 (1976)
2. American Gastroenterological Association, "American Gastroenterological Association medical position statement on the management of Barrett’s esophagus", Gastroenterology, 140, pp.1084~1091 (2011)
3. Fitzgerald RC, "British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus", Gut, 63, pp.7~42 (2014)
4. Zagari RM, "Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study", Gut, 57, pp.1354~1359 (2008)
5. Ronkainen J, "Prevalence of Barrett’s esophagus in the general population: an endoscopic study", Gastroenterology, 129, pp.1825~1831 (2005)
6. Connor MJ, "The prevalence of Barrett’s esophagus and erosive esophagitis in patients undergoing upper endoscopy for dyspepsia in a VA population", Dig Dis Sci, 49, pp.920~924 (2004)
7. Winters C Jr, "Barrett’s esophagus: a prevalent, occult complication of gastroesophageal reflux disease", Gastroenterology, 92, pp.118~124 (1987)
8. Bhat S, "Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study", J Natl Cancer Inst, 103, pp.1049~1057 (2011)
9. Desai TK, "The incidence of esophageal adenocarcinoma among patients with nondysplastic Barrett’s esophagus has been overestimated", Clin Gastroenterol Hepatol, 9, pp.363~364 (2011)
10. Hvid-Jensen F, "Long-term complications to reflux disease in community practice: a 17-year cohort study of 4706 patients", Scand J Gastroenterol, 46, pp.1179~1186 (2011)
11. Sundelöf M, "Improved survival in both histologic types of oesophageal cancer in Sweden", Int J Cancer, 99, pp.751~754 (2002)
12. "Oesophageal cancer statistics" (2012)[URL]
13. Eloubeidi MA, "Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope?", Am J Gastroenterol, 98, pp.1627~1633 (2003)
14. "GLOBOCAN 2008 v1.2: cancer incidence and mortality worldwide: IARC CancerBase No. 10" (2010)[URL]
15. Pohl H, "Esophageal adenocarcinoma incidence: are we reaching the peak?", Cancer Epidemiol Biomarkers Prev, 19, pp.1468~1470 (2010)
16. Thrift AP, "The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends", Ann Oncol, 23, pp.3155~3162 (2012)
17. Millikan KW, "A 15-year review of esophagectomy for carcinoma of the esophagus and cardia", Arch Surg, 130, pp.617~624 (1995)
18. Rice TW, "Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status", Ann Thorac Surg, 65, pp.787~792 (1998)
19. Kennedy T, "The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms", Aliment Pharmacol Ther, 14, pp.1589~1594 (2000)
20. Locke GR 3rd, "Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota", Gastroenterology, 112, pp.1448~1456 (1997)
21. Peery AF, "Burden of gastrointestinal disease in the United States: 2012 update", Gastroenterology, 143, pp.1179~1187 (2012)
22. di Pietro M, "Screening and risk stratification for Barrett’s esophagus: how to limit the clinical impact of the increasing incidence of esophageal adenocarcinoma", Gastroenterol Clin North Am, 42, pp.155~173 (2013)
23. Anderson LA, "Risk factors for Barrett’s oesophagus and oesophageal adenocarcinoma: results from the FINBAR study", World J Gastroenterol, 13, pp.1585~1594 (2007)
24. Taylor JB, "Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett’s esophagus", Am J Gastroenterol, 105, pp.1729~1737 (2010)
25. Stein DJ, "The association of body mass index with Barrett’s oesophagus", Aliment Pharmacol Ther, 22, pp.1005~1010 (2005)
26. Smith KJ, "Interactions among smoking, obesity, and symptoms of acid reflux in Barrett’s esophagus", Cancer Epidemiol Biomarkers Prev, 14(11 Pt 1), pp.2481~2486 (2005)
27. Akiyama T, "Visceral obesity and the risk of Barrett’s esophagus in Japanese patients with non-alcoholic fatty liver disease", BMC Gastroenterol, 9, pp.56~ (2009)
28. El-Serag HB, "Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett’s oesophagus: a case-control study", Gut, 63, pp.220~229 (2014)
29. Cook MB, "Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium", J Natl Cancer Inst, 102, pp.1344~1353 (2010)
30. Cook MB, "Cigarette smoking increases risk of Barrett’s esophagus: an analysis of the Barrett’s and Esophageal Adenocarcinoma Consortium", Gastroenterology, 142, pp.744~753 (2012)
31. Thrift AP, "No significant effects of smoking or alcohol consumption on risk of Barrett’s esophagus", Dig Dis Sci, 59, pp.108~116 (2014)
32. Hvid-Jensen F, "Incidence of adenocarcinoma among patients with Barrett’s esophagus", N Engl J Med, 365, pp.1375~1383 (2011)
33. Islami F, "Helicobacter pylori and esophageal cancer risk: a meta-analysis", Cancer Prev Res (Phila), 1, pp.329~338 (2008)
34. Kubo A, "Dietary factors and the risks of oesophageal adenocarcinoma and Barrett’s oesophagus", Nutr Res Rev, 23, pp.230~246 (2010)
35. Rex DK, "Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn", Gastroenterology, 125, pp.1670~1677 (2003)
36. Verbeek RE, "Familial clustering of Barrett’s esophagus and esophageal adenocarcinoma in a European cohort", Clin Gastroenterol Hepatol (2014)[DOI]
37. Chak A, "Familiality in Barrett’s esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction", Cancer Epidemiol Biomarkers Prev, 15, pp.1668~1673 (2006)
38. Juhasz A, "Prevalence of Barrett esophagus in first-degree relatives of patients with esophageal adenocarcinoma", J Clin Gastroenterol, 45, pp.867~871 (2011)
39. Su Z, "Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett’s esophagus", Nat Genet, 44, pp.1131~1136 (2012)
40. Levine DM, "A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett’s esophagus", Nat Genet, 45, pp.1487~1493 (2013)
41. Wang X, "Residual embryonic cells as precursors of a Barrett’s-like metaplasia", Cell, 145, pp.1023~1035 (2011)
42. Quante M, "Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia", Cancer Cell, 21, pp.36~51 (2012)
43. Souza RF, "Acid, bile, and CDX: the ABCs of making Barrett’s metaplasia", Am J Physiol Gastrointest Liver Physiol, 295, pp.G211~G218 (2008)
44. Liu T, "Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells", Carcinogenesis, 28, pp.488~496 (2007)
45. Colleypriest BJ, "Cdx genes, inflammation and the pathogenesis of Barrett’s metaplasia", Trends Mol Med, 15, pp.313~322 (2009)
46. di Pietro M, "Evidence for a functional role of epigenetically regulated midcluster HOXB genes in the development of Barrett esophagus", Proc Natl Acad Sci U S A, 109, pp.9077~9082 (2012)
47. Barbera M, "The human squamous oesophagus has widespread capacity for clonal expansion from cells at diverse stages of differentiation", Gut (2014)[DOI]
48. Dvorak K, "Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett’s oesophagus", Gut, 56, pp.763~771 (2007)
49. Vaninetti NM, "Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett’s esophagus and esophageal adenocarcinoma", Mol Carcinog, 47, pp.275~285 (2008)
50. Sihvo EI, "Oxidative stress has a role in malignant transformation in Barrett’s oesophagus", Int J Cancer, 102, pp.551~555 (2002)
51. Clemons NJ, "Nitric oxide and acid induce double-strand DNA breaks in Barrett’s esophagus carcinogenesis via distinct mechanisms", Gastroenterology, 133, pp.1198~1209 (2007)
52. Cardin R, "Oxidative DNA damage in Barrett mucosa: correlation with telomeric dysfunction and p53 mutation", Ann Surg Oncol, 20(Suppl 3), pp.S583~S589 (2013)
53. Berndt U, "Comparative Multi-Epitope-Ligand-Cartography reveals essential immunological alterations in Barrett’s metaplasia and esophageal adenocarcinoma", Mol Cancer, 9, pp.177~ (2010)
54. Salmela MT, "Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett’s oesophageal adenocarcinoma", Br J Cancer, 85, pp.383~392 (2001)
55. Bobryshev YV, "Dendritic cell-associated immune inflammation of cardiac mucosa: a possible factor in the formation of Barrett’s esophagus", J Gastrointest Surg, 13, pp.442~450 (2009)
56. Picardo SL, "Barrett’s to oesophageal cancer sequence: a model of inflammatory-driven upper gastrointestinal cancer", Dig Surg, 29, pp.251~260 (2012)
57. Matsuzaki J, "Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis", Gastroenterology, 145, pp.1300~1311 (2013)
58. Bus P, "Upregulation of miRNA-143, -145, -192, and -194 in esophageal epithelial cells upon acidic bile salt stimulation", Dis Esophagus (2013)
59. van Baal JW, "microRNA-145 in Barrett’s oesophagus: regulating BMP4 signalling via GATA6", Gut, 62, pp.664~675 (2013)
60. Wang DH, "Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett’s metaplasia", Gastroenterology, 138, pp.1810~1822 (2010)
61. Bansal A, "Discovery and validation of Barrett’s esophagus microRNA transcriptome by next generation sequencing", PLoS One, 8, pp.e54240~ (2013)
62. Saad R, "Deciphering the unique microRNA signature in human esophageal adenocarcinoma", PLoS One, 8, pp.e64463~ (2013)
63. Mitchell PS, "Circulating microRNAs as stable blood-based markers for cancer detection", Proc Natl Acad Sci U S A, 105, pp.10513~10518 (2008)
64. Qiu MT, "Long noncoding RNA: an emerging paradigm of cancer research", Tumour Biol, 34, pp.613~620 (2013)
65. Wu W, "Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett’s esophagus and esophageal adenocarcinoma", Gastroenterology, 144, pp.956~966 (2013)
66. Curvers WL, "Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated", Am J Gastroenterol, 105, pp.1523~1530 (2010)
67. Wani S, "Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus", Gastroenterology, 141, pp.1179~1186 (2011)
68. Sikkema M, "Predictors for neoplastic progression in patients with Barrett’s esophagus: a prospective cohort study", Am J Gastroenterol, 106, pp.1231~1238 (2011)
69. Wani S, "Patients with nondysplastic Barrett’s esophagus have low risks for developing dysplasia or esophageal adenocarcinoma", Clin Gastroenterol Hepatol, 9, pp.220~227 (2011)
70. Weston AP, "Risk stratification of Barrett’s esophagus: updated prospective multivariate analysis", Am J Gastroenterol, 99, pp.1657~1666 (2004)
71. Bennett C, "Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process", Gastroenterology, 143, pp.336~346 (2012)
72. Galipeau PC, "Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett’s) tissue", J Natl Cancer Inst, 91, pp.2087~2095 (1999)
73. Merlo LM, "Polyploidy, aneuploidy and the evolution of cancer", Adv Exp Med Biol, 676, pp.1~13 (2010)
74. Lai LA, "Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH", Genes Chromosomes Cancer, 46, pp.532~542 (2007)
75. Paulson TG, "p16 mutation spectrum in the premalignant condition Barrett’s esophagus", PLoS One, 3, pp.e3809~ (2008)
76. Reid BJ, "Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets", Am J Gastroenterol, 95, pp.1669~1676 (2000)
77. Reid BJ, "Predictors of progression in Barrett’s esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression", Am J Gastroenterol, 96, pp.2839~2848 (2001)
78. Galipeau PC, "NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma", PLoS Med, 4, pp.e67~ (2007)
79. Dunn JM, "Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett’s oesophagus following photodynamic therapy", Br J Cancer, 102, pp.1608~1617 (2010)
80. Bird-Lieberman EL, "Population-based study reveals new risk-stratification biomarker panel for Barrett’s esophagus", Gastroenterology, 143, pp.927~935 (2012)
81. Rygiel AM, "Assessment of chromosomal gains as compared to DNA content changes is more useful to detect dysplasia in Barrett’s esophagus brush cytology specimens", Genes Chromosomes Cancer, 47, pp.396~404 (2008)
82. Rygiel AM, "Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett’s esophagus", Cancer Epidemiol Biomarkers Prev, 17, pp.1380~1385 (2008)
83. Fritcher EG, "A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett’s esophagus", Hum Pathol, 39, pp.1128~1135 (2008)
84. Dulak AM, "Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity", Nat Genet, 45, pp.478~486 (2013)
85. Nakashima S, "Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma", Anticancer Res, 20(3B), pp.1933~1937 (2000)
86. Kaye PV, "Novel staining pattern of p53 in Barrett’s dysplasia: the absent pattern", Histopathology, 57, pp.933~935 (2010)
87. Murray L, "TP53 and progression from Barrett’s metaplasia to oesophageal adenocarcinoma in a UK population cohort", Gut, 55, pp.1390~1397 (2006)
88. Kastelein F, "Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett’s oesophagus", Gut, 62, pp.1676~1683 (2013)
89. Kaye PV, "Barrett’s dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry", Histopathology, 54, pp.699~712 (2009)
90. Esteller M, "Cancer epigenomics: DNA methylomes and histone-modification maps", Nat Rev Genet, 8, pp.286~298 (2007)
91. Kaz AM, "DNA methylation profiling in Barrett’s esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses", Epigenetics, 6, pp.1403~1412 (2011)
92. Alvi MA, "DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett’s esophagus", Clin Cancer Res, 19, pp.878~888 (2013)
93. Wang JS, "DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett’s esophagus", Am J Gastroenterol, 104, pp.2153~2160 (2009)
94. Schulmann K, "Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett’s-associated neoplastic progression and predicts progression risk", Oncogene, 24, pp.4138~4148 (2005)
95. Lao-Sirieix P, "Cyclin A immunocytology as a risk stratification tool for Barrett’s esophagus surveillance", Clin Cancer Res, 13(2 Pt 1), pp.659~665 (2007)
96. ASGE Standards of Practice Committee, "The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus", Gastrointest Endosc, 76, pp.1087~1094 (2012)
97. Lagergren J, "Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma", N Engl J Med, 340, pp.825~831 (1999)
98. Cooper GS, "Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends", Am J Gastroenterol, 104, pp.1356~1362 (2009)
99. Fountoulakis A, "Effect of surveillance of Barrett’s oesophagus on the clinical outcome of oesophageal cancer", Br J Surg, 91, pp.997~1003 (2004)
100. Rubenstein JH, "Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans", Gastrointest Endosc, 68, pp.849~855 (2008)
101. Corley DA, "Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas", Gastroenterology, 145, pp.312~319 (2013)
102. Spechler SJ, "American Gastroenterological Association. American Gastroenterological Association technical review on the management of Barrett’s esophagus", Gastroenterology, 140, pp.e18~e52 (2011)
103. "ISRCTN"[URL]
104. Singh S, "Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis", Gut (2013)[DOI]
105. Buttar NS, "The effect of selective cyclooxygenase-2 inhibition in Barrett’s esophagus epithelium: an in vitro study", J Natl Cancer Inst, 94, pp.422~429 (2002)
106. Vaughan TL, "Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study", Lancet Oncol, 6, pp.945~952 (2005)
107. Falk GW, "A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett’s esophagus", Gastroenterology, 143, pp.917~926 (2012)
108. Ngamruengphong S, "Diagnostic yield of methylene blue chromoendoscopy for detecting specialized intestinal metaplasia and dysplasia in Barrett’s esophagus: a meta-analysis", Gastrointest Endosc, 69, pp.1021~1028 (2009)
109. Kara MA, "High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett’s esophagus: a prospective randomized crossover study", Endoscopy, 37, pp.929~936 (2005)
110. Ferguson DD, "Enhanced magnification-directed biopsies do not increase the detection of intestinal metaplasia in patients with GERD", Am J Gastroenterol, 101, pp.1611~1616 (2006)
111. Hoffman A, "Acetic acid-guided biopsies after magnifying endoscopy compared with random biopsies in the detection of Barrett’s esophagus: a prospective randomized trial with crossover design", Gastrointest Endosc, 64, pp.1~8 (2006)
112. Longcroft-Wheaton G, "Acetic acid spray is an effective tool for the endoscopic detection of neoplasia in patients with Barrett’s esophagus", Clin Gastroenterol Hepatol, 8, pp.843~847 (2010)
113. Muto M, "Narrow band imaging: a new diagnostic approach to visualize angiogenesis in superficial neoplasia", Clin Gastroenterol Hepatol, 3(7 Suppl 1), pp.S16~S20 (2005)
114. Wolfsen HC, "Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia detection in Barrett’s Esophagus", Gastroenterology, 135, pp.24~31 (2008)
115. Sharma P, "Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett’s oesophagus: a prospective, international, randomised controlled trial", Gut, 62, pp.15~21 (2013)
116. Mannath J, "Narrow band imaging for characterization of high grade dysplasia and specialized intestinal metaplasia in Barrett’s esophagus: a meta-analysis", Endoscopy, 42, pp.351~359 (2010)
117. Kara MA, "Endoscopic video-autofluorescence imaging followed by narrow band imaging for detecting early neoplasia in Barrett’s esophagus", Gastrointest Endosc, 64, pp.176~185 (2006)
118. Kara MA, "Endoscopic video autofluorescence imaging may improve the detection of early neoplasia in patients with Barrett’s esophagus", Gastrointest Endosc, 61, pp.679~685 (2005)
119. Curvers WL, "Endoscopic tri-modal imaging for detection of early neoplasia in Barrett’s oesophagus: a multi-centre feasibility study using high-resolution endoscopy, autofluorescence imaging and narrow band imaging incorporated in one endoscopy system", Gut, 57, pp.167~172 (2008)
120. Curvers WL, "Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett’s esophagus", Gastroenterology, 139, pp.1106~1114 (2010)
121. Curvers WL, "Endoscopic trimodal imaging versus standard video endoscopy for detection of early Barrett’s neoplasia: a multicenter, randomized, crossover study in general practice", Gastrointest Endosc, 73, pp.195~203 (2011)
122. di Pietro M, "The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett’s oesophagus", Gut (2014)[DOI]
123. Boerwinkel DF, "Endoscopic TriModal imaging and biomarkers for neoplasia conjoined: a feasibility study in Barrett’s esophagus", Dis Esophagus (2012)[DOI]
124. Gupta A, "Utility of confocal laser endomicroscopy in identifying high-grade dysplasia and adenocarcinoma in Barrett’s esophagus: a systematic review and meta-analysis", Eur J Gastroenterol Hepatol, 26, pp.369~377 (2014)
125. Sharma P, "Real-time increased detection of neoplastic tissue in Barrett’s esophagus with probe-based confocal laser endomicroscopy: final results of an international multicenter, prospective, randomized, controlled trial", Gastrointest Endosc, 74, pp.465~472 (2011)
126. Canto MI, "In vivo endo microscopy improves detection of Barrett’s esophagus-related neoplasia: a multicenter international randomized controlled trial (with video)", Gastrointest Endosc, 79, pp.211~221 (2014)
127. Bouma BE, "High-resolution imaging of the human esophagus and stomach in vivo using optical coherence tomography", Gastrointest Endosc, 51(4 Pt 1), pp.467~474 (2000)
128. Evans JA, "Optical coherence tomography to identify intramucosal carcinoma and high-grade dysplasia in Barrett’s esophagus", Clin Gastroenterol Hepatol, 4, pp.38~43 (2006)
129. Georgakoudi I, "Fluorescence, reflectance, and light-scattering spectroscopy for evaluating dysplasia in patients with Barrett’s esophagus", Gastroenterology, 120, pp.1620~1629 (2001)
130. Wallace MB, "Endoscopic detection of dysplasia in patients with Barrett’s esophagus using light-scattering spectroscopy", Gastroenterology, 119, pp.677~682 (2000)
131. Wilson BC, "Detection and treatment of dysplasia in Barrett’s esophagus: a pivotal challenge in translating biophotonics from bench to bedside", J Biomed Opt, 12, pp.051401~ (2007)
132. Abrams JA, "Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States", Clin Gastroenterol Hepatol, 7, pp.736~742 (2009)
133. Gupta N, "Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus", Gastrointest Endosc, 76, pp.531~538 (2012)

관련 논문AI추천